Intellectus Partners LLC Boosts Holdings in Illumina, Inc. (NASDAQ:ILMN)

Intellectus Partners LLC lifted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 14.3% in the third quarter, Holdings Channel reports. The firm owned 15,440 shares of the life sciences company’s stock after buying an additional 1,935 shares during the period. Intellectus Partners LLC’s holdings in Illumina were worth $2,014,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of ILMN. Versant Capital Management Inc increased its stake in Illumina by 292.9% during the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock worth $34,000 after buying an additional 246 shares in the last quarter. Industrial Alliance Investment Management Inc. acquired a new stake in shares of Illumina in the second quarter worth approximately $34,000. Massmutual Trust Co. FSB ADV increased its position in shares of Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after purchasing an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new position in Illumina in the 2nd quarter valued at $61,000. Finally, Mizuho Securities Co. Ltd. purchased a new position in Illumina in the 2nd quarter valued at $63,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Down 2.7 %

ILMN opened at $142.24 on Friday. Illumina, Inc. has a 52 week low of $92.69 and a 52 week high of $156.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The business has a fifty day simple moving average of $139.20 and a 200-day simple moving average of $124.10.

Illumina (NASDAQ:ILMN) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. Illumina’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same period last year, the business posted $0.33 EPS. On average, equities analysts predict that Illumina, Inc. will post 4.11 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently issued reports on ILMN. HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a report on Thursday, October 17th. Hsbc Global Res upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective for the company in a report on Thursday, October 17th. Daiwa America upgraded Illumina to a “strong-buy” rating in a report on Friday, August 16th. StockNews.com started coverage on Illumina in a research report on Thursday, August 29th. They issued a “buy” rating for the company. Finally, Argus upgraded Illumina from a “hold” rating to a “buy” rating and set a $150.00 price objective on the stock in a research report on Wednesday, August 28th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $164.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.